Novel Therapies for Cancer and Emerging Targets banner

The field of biologic drug development for cancer therapies has been greatly energized by the broad spectrum of innovative approaches and their stunning success. The Novel Therapies for Cancer and Emerging Targets track at PEGS Europe will provide a comprehensive picture of the preclinical and clinical development of novel biotherapeutics against cancer, including bispecific, ADC and immunotherapy approaches. Recent results will be reviewed and analyzed to reveal insights into why some strategies fail while others prove to be successful. New approaches to making immunotherapies safer and more effective will be considered and latest clinical progress will be shared. A session dedicated to emerging targets will be featured.

Final Agenda

Scientific Advisory Board

Kerry Chester, PhD, Professor, Molecular Medicine, University College London Cancer Institute

Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital, Harvard Medical School

Mitchell Ho, PhD, Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH

Horacio G. Nastri, PhD, Senior Director, Antibody Biotherapeutics, Incyte Corporation


13:00 Registration (Foyer C)

13:15 Dessert Break in the Exhibit Hall with Poster Viewing (Pavilion 1)

Auditorium VIII

14:00 Chairperson’s Opening Remarks

Kerry Chester, PhD, Professor, Molecular Medicine, University College London Cancer Institute

14:05 TGFβ Drives Immune Evasion in Genetically Reconstituted Colon Cancer Metastasis

Tauriello_DanieleDaniele Tauriello, PhD, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology

We crossed mice bearing conditional alleles of four main colorectal cancer mutations in intestinal stem cells. From the resulting tumours, we derived organoids to transplant in syngeneic, immunocompetent mice. Cancers display key hallmarks of human microsatellite-stable colorectal cancers. Inhibition of TGFβ unleashed a potent cytotoxic T-cell response against tumour cells, preventing metastatic initiation in mice with progressive liver metastatic disease, blockade of TGFβ signalling rendered tumours susceptible to anti-PD-1/PD-L1 therapy.

14:35 Developing an ROR1 Bispecific T-Cell Engager for Treatment of Solid Tumors

Amit C. Nathwani, PhD, Professor, Haematology, University College London

We have developed a humanized Bi-Specific T-Cell Engager (BiTE) targeting Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1), a cell surface antigen present on a broad range of malignancies, many with significant unmet therapeutic needs. In preclinical studies, the ROR1 BiTE-mediated T cell and tumour antigen-specific cytotoxicity against of a range of histologically distinct, ROR1 expressing solid tumour cell lines at exceedingly low concentrations (0.1ng/mL) and low effector to target ratios. In vivo studies showed that the ROR1-BiTE prevented engraftment of tumour in xenograft murine models and significantly reduced the size of established subcutaneous tumours. To validate its wider therapeutic potential, we next demonstrated significant cytotoxicity against ovarian cancer in an in vitro and in vivo setting and T cell mediated killing. Final preclinical data to support a clinical trial will be presented together the obstacles encountered in the generation of clinical grade ROR1-BiTE, a promising immunotherapy approach.